SEATTLE and VANCOUVER, British Columbia, March 18, 2019 /PRNewswire/ -- Achieve Life
Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical
company committed to the global development and commercialization
of cytisinicline for smoking cessation, today announced that
Rick Stewart, Chairman and Chief
Executive Officer, will present at Oppenheimer's 29th Annual
Healthcare Conference in New York
on Wednesday, March 20 at
2:10 p.m. Eastern Time.
A live webcast of the presentation can be accessed at
http://ir.achievelifesciences.com/events-and-webcasts. A replay of
the webcast will also be archived on Achieve's website following
the conference.
About Achieve
Tobacco use is currently the leading
cause of preventable death and is responsible for nearly seven
million deaths annually worldwide1. It is estimated that
28.7% of cancer deaths in the U.S. are attributable to cigarette
smoking2.
Achieve's focus is to address the global smoking health epidemic
through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in smoking cessation by interacting with nicotine receptors in
the brain by reducing the severity of nicotine withdrawal symptoms
and by reducing the reward and satisfaction associated with
smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it
is estimated that over 20 million people have used cytisinicline to
help combat nicotine addiction.
Achieve Contact
Jason
Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
1 World Health Organization. WHO Report on the
Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017
2 Annals of Epidemiology, Volume 25, Issue 3, 179 -
182.e1
View original content to download
multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-to-present-at-oppenheimers-29th-annual-healthcare-conference-on-march-20-2019-300813491.html
SOURCE Achieve Life Sciences, Inc.